ZSZafer Söylemez

Zafer Söylemez

*This is an algorithmically generated author record based on publicly available information.

Zafer Söylemez has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    COMPARISON OF THE EFFECTS OF DOCETAXEL and AMYGDALIN TREATMENT ON CELL DEATH, INTEGRIN-α and INTEGRIN-β EXPRESSIONS IN DU145 PROSTATE CANCER CELL LINE

    by Çiğdem Karaca, Evrim Suna Arıkan Söylemez, Esra Aslan, Fatma Fırat, Zafer Söylemez

    OBJECTIVE: Prostate cancer (PC) ranks second among cancer-related deaths in men, and most deaths are caused by metastasis. Integrins, which are cell surface receptors, play an important role in cancer metastasis. It has been shown that integrin alpha2beta1 expression is effective in cell adhesion, migration, and invasion by increasing binding to collagen I in metastatic PCs. Docetaxel chemotherapy is used in PC, but it is ineffective in advanced stages. Amygdalin is a cyanogenic glycoside commonly found in fruit seeds, there is conflict in the literature regarding its effectiveness in cancer treatment. We aimed to compare the effects of Amygdalin and Docetaxel treatments on the DU145 prostate cancer cell line on integrinalfa2 (ITGA2) and integrinbeta1 (ITGB1) expressions, as well as their effects on cell death, Caspase-3, and Beclin-1. MATERIAL AND METHODS: Propagated DU145 cells were divided into four groups. Amygdalin was given to the first group, Docetaxel was given to the second group, and Amygdalin andDocetaxel were given together to the third group. They were exposed to the active substances for 24 hours. The fourth group (Control) was not given any substance. mRNA levels of ITGA2 and ITGB1 genes were determined by the Real-time PCR method. Caspase-3 and Beclin-1 staining were performed immunocytochemically to evaluate cell death. RESULTS: There was an increase in ITGA2 and ITGB1 expressions in the groups administered by Amygdalin and by Docetaxel (P<0.05). The decrease in ITGB1 expression was significant in the group given Amygdalin+Docetaxel (P<0.001). Caspase-3 (P<0.05) and Beclin-1 (P<0.05) immunoreactivities were observed to increase in all three groups compared to the control group. CONCLUSIONS: It was observed that Docetaxel increased cell death more than Amygdalin in DU145 PC cells, and when Amygdalin and Docetaxel were used together, ITGA2 and ITGB1 expressions were significantly reduced. Our results suggest that dual treatment of Amygdalin and Docetaxel may prevent prostate cancer metastases.


  • Transkriptomik ve Uygulamaları

    by Evrim Suna Arıkan Söylemez, Zafer Söylemez

    In recent years, an explosion has occurred in the acquisition of biological data through the use of so-called ‘omics’ techniques. Whilst many different omics technologies are now featured in the literature, the most frequently used omics are genomics, transcriptomics, proteomics and metabolomics. A transcriptome is the complete set and quantity of all RNA molecules produced by the genome at any given time for a particular developmental stage or physiological state in a cell, a population of cells, or an organism. Transcriptomics is regarded as a highthroughput technology concerned with determining how the transcriptome changes with respect to various factors at a certain time point and at a given biological state. The study of the transcriptome is essential for understanding the functional elements of the genome and revealing the molecular constituents of cells. Nowadays, transcriptomics have come to the forefront of international scientific attention due to the rapid development of RNA-sequencing (RNA-Seq) methods. The key aim of transcriptomics is precise, comprehensive characterization of the transcriptome; the annotation of all species of transcript, including mRNAs, non-coding RNAs, such as small RNAs, the determination of the transcriptional structure of genes, and the quantification of differential expression levels of each transcript under different conditions. Generally, the goal of transcriptome analysis is to identify genes differentially expressed among different conditions, leading to a new understanding of the genes or pathways associated with the conditions. This chapter provides fundamental information into the promising technology of transcriptomics.

  • Open Access

    Investigation of the expression levels of CPEB4, APC, TRIP13, EIF2S3, EIF4A1, IFNg, PIK3CA and CTNNB1 genes in different stage colorectal tumors

    by Zafer Söylemez, Evrim Suna Arikan, Mustafa Solak, Yüksel Arikan, Çiğdem Tokyol, Hüseyin Şeker

    The aim of the study is to assess expression levels of CPEB4, APC, TRIP13, EIF2S3, EIF4A, IFN?, PIK3CA and CTNNB1 genes in tumors and peripheral bloods of colorectal cancer patients in staged I-IV. The mRNA levels of the genes were determined in tumor tissues and peripheral blood samples of 45 colorectal cancer patients and colon tissues and peripheral blood samples of 5 healthy individuals. Real Time Polymerase Chain Reaction method was used for the analysis. The mRNA level of the CPEB4 gene was significantly downregulated in colorectal tumor tissues and was upregulated in the peripheral blood of colorectal cancer patients relative to the controls (P?0,05). APC mRNA level was significantly downregulated in tissues and upregulated in the peripheral blood (P?0,05). TRIP13 mRNA level was upregulated in peripheral blood and also significantly upregulated in colorectal tumor tissues (P?0,05). EIF2S3 mRNA level was upregulated in tissues and also significantly upregulated in peripheral blood (P?0.05). PIK3CA mRNA level was downregulated in tissues and upregulated in peripheral blood. EIF4A1 mRNA level was downregulated in tissues and significantly upregulated in peripheral blood (P?0.05). CTNNB1 mRNA level was downregulated in tissues and upregulated in peripheral blood. IFN? mRNA level was upregulated in both colorectal cancer tumor tissues and peripheral blood. TRIP13 and CPEB4 mRNA up regulation in the peripheral blood of patients with colorectal cancer may be a potential target for early stage diagnosis. Although there is not much study on EIF2S3 and EIF4A1 mRNA changes in cases with colorectal cancer, upregulation in peripheral blood draws attention in our study. These data will shed light on the new comprehensive studies.


  • Open Access

    Investigation of the expression levels of CDH1, FHIT, PTEN and TTPAL genes in colorectal tumors

    by Evrim Suna Arikan Soylemez, Zafer Soylemez, Murat Cilekar, Yuksel Arikan, Cigdem Tokyol, Ibrahim Halil Kenger, Mustafa Solak

    Background/aim: The main aim of the study is to assess expression levels of CDH1, FHIT, PTEN, and TTPAL genes in tumors and peripheral bloods of colorectal cancer patients in staged I-IV. Materials and methods: Gene expression analysis of related genes were performed for tumor tissues and peripheral blood samples of 51 colorectal cancer patients and colon tissues and blood samples of 5 healthy individuals. The real-time-PCR reaction method was used for the analysis. Results: Alteration of mRNA levels of related genes in tumor tissues of colorectal cancer cases was determined compared to control tissues. GAPDH and TBP were used for the normalization. While the mRNA levels of CDH1 decreased, the mRNA level of the FHIT and TTPAL genes increased in the tumor tissues. There was no PTEN gene expression difference in tumor tissues (total). The mRNA levels of the CDH1 and PTEN genes were increased while the mRNA levels of FHIT and TTPAL genes decreased in the blood (total). The mRNA levels of the CDH1 gene decreased at each stage (I-IV) in the tumor tissues and increased at each stage (I-IV) in the blood. The PTEN gene mRNA levels at each stage were controversial. The mRNA levels of the FHIT gene increased at stage I-II-III, decreased at stage IV in the tissues and decreased at each stage (I-IV) in the blood. The mRNA levels of TTPAL gene increased at each stage (I-IV) in the tissues and decreased at each stage (I-IV) in the blood. Conclusion: Although related expression levels in tissue did not correlate with its expression in blood, consistent with previous studies FHIT and TTPAL genes upregulation and CDH1 downregulation, in especially tumoral tissues, may serve as predictive determinants for the patients with colorectal cancer.